• 1
    Haaff EO, Catalona WJ, Ratliff TL. Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol 1986; 136: 970974.
  • 2
    deBoer EC, deJong WH, Steerenberg PA, Aarden LA, Tetteroo E., deGroot ER, van derMeijden APM, Vegt PDJ, deBruyne FMJ, Ruitenberg EJ. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumor necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother 1992; 34: 306312.
  • 3
    deBoer EC, deJong WH, van derMeijden APM, Witjes F., Vegt PDJ, deBruyne FMJ, Ruitenberg EJ. Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. Urol Res 1991; 19: 4550.
  • 4
    deBoer EC, deJong WH, van derMeijden APM, Steerenberg PA, Witjes JA, Vegt PDJ, deBruyne FMJ, Ruitenberg EJ. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin. Cancer Immunol Immunother 1991; 33: 411416.
  • 5
    Bohle A.. Prospects for improving the efficacy of BCG. Eur Urol 1992; 21(suppl 2):2227.
  • 6
    Winters WD, Lamm DL. Antibody responses to bacillus Calmette-Guérin during immunotherapy in bladder cancer patients. Cancer Res 1981; 41: 26722676.
  • 7
    Torrence RJ, Kavoussi LR, Catalona WJ, Ratliff TL. Prognostic factors in patients treated with intravesical bacillus Calmette-Guérin for superficial bladder cancer. J Urol 1988; 139: 941946.
  • 8
    Conti P., Reale M., Nicolai M., Barbacane RC, Placido FC, Iantorno R., Tenaglia R. Bacillus Calmette-Guerin potentiates monocyte responses to lipopolysaccharide-induced tumor necrosis factor and interleukin-1, but not interleukin-6 in bladder cancer patients. Cancer Immunol Immunother 1994; 38: 365371.
  • 9
    Mizutani Y., Nio Y., Fukumoto M., Yoshida O. Effects of bacillus Calmette-Guérin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer. Cancer 1992; 69: 537545.
  • 10
    Hermann GG, Petersen KR, Zeuthen J., Steven K.. Intravesical BCG therapy in bladder carcinoma. Scand J Urol Nephrol 1991; 25: 269273.
  • 11
    Kaasinen ES, Kalliomaki PHW, Alfthan OS, Timonen TT. Bacillus Calmette-Guérin sensitises fresh transitional carcinoma cells and T24 cell line to non-MHC-restricted cytotoxicity in vitro. Br J Urol 1993; 72: 897906.
  • 12
    Atzpodien J., Kirchner H., Korfer A., Hadam M., Schomburg A., Menzel T., deCkert M., Franzke A., Volkenandt M., Dallmann I., Grosse J., Poliwoda H.. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-α2. Tumor Biol 1993; 14: 354359.
  • 13
    Mizutani Y., Okada Y., Terachi T., Yoshida O. Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer. J Urol 1996; 155: 888894.
  • 14
    Jakse G., Members of the EORTC-GU Group. Intravesical instillation of BCG in carcinoma in situ of the urinary bladder. EORTC protocol 30861. In: deBruyneFMJ, deNisL. van derMeijdenAPM, (eds) EORTC Genitourinary Group Monograph 6: BCG in superficial bladder cancer. New York : Alan R Liss, 1989: 187192.
  • 15
    Bohle A., Gerdes J., Ulmer AJ, Hofstetter AG, Flad H-D. Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 1990; 144: 5357.
  • 16
    Herr WH, Whitemore WF. Ureteral carcinoma in situ after successful intravesical therapy for superficial bladder tumors: incidence, possible pathogenesis and management. J Urol 1987; 138: 292294.